ACADIA PHARMACEUTICALS INC. (ACAD) Scorecard
- 2026-Q2: Total return Lose; Revenue growth Lose; EPS growth Win.
- 2026-Q1: Total return Lose; Revenue growth Lose; EPS growth Win.
- 2025-Q4: Total return Win; Revenue growth Win; EPS growth Win.
- 2025-Q3: Total return Lose; Revenue growth Win; EPS growth Win.
53/120
All 120 Win/Lose results shown below
Every strict quarterly win earns 1 point. A loss, tie, or unavailable scoring value earns 0.
Trailing 1 year (4 quarters): 7 wins, 5 lossesLast fetched: 4 Sept 2026
Complete point ledger
Each cell identifies the missing side explicitly.
| Quarter | Total return | Revenue growth | EPS growth |
|---|---|---|---|
| 2026-Q21/3 |
LoseACAD / S&P 13.66% / 15.20% |
LoseACAD / S&P 11.75% / 15.00% |
WinACAD / S&P 67.67% / 50.40% |
| 2026-Q11/3 |
LoseACAD / S&P -16.66% / -4.33% |
LoseACAD / S&P 9.93% / 11.30% |
WinACAD / S&P 61.31% / 27.70% |
| 2025-Q43/3 |
WinACAD / S&P 25.16% / 2.65% |
WinACAD / S&P 11.87% / 9.00% |
WinACAD / S&P 69.12% / 13.40% |
| 2025-Q32/3 |
LoseACAD / S&P -1.07% / 8.12% |
WinACAD / S&P 12.69% / 4.61% |
WinACAD / S&P 98.72% / 13.45% |
| 2025-Q23/3 |
WinACAD / S&P 29.86% / 10.94% |
WinACAD / S&P 14.41% / 4.83% |
WinACAD / S&P 638.89% / 10.63% |
| 2025-Q11/3 |
LoseACAD / S&P -9.48% / -4.27% |
WinACAD / S&P 22.42% / 4.98% |
LoseACAD / S&P -13800.00% / 10.57% |
| 2024-Q42/3 |
WinACAD / S&P 19.31% / 2.41% |
WinACAD / S&P 31.85% / 5.25% |
LoseACAD / S&P -457.89% / 6.15% |
| 2024-Q31/3 |
LoseACAD / S&P -5.35% / 5.89% |
WinACAD / S&P 47.06% / 5.89% |
LoseACAD / S&P -184.78% / 6.11% |
| 2024-Q21/3 |
LoseACAD / S&P -12.11% / 4.28% |
WinACAD / S&P 61.65% / 5.38% |
LoseACAD / S&P -126.09% / 5.12% |
| 2024-Q11/3 |
LoseACAD / S&P -40.95% / 10.56% |
WinACAD / S&P 56.43% / 5.71% |
LoseACAD / S&P -98.90% / 5.59% |
| 2023-Q42/3 |
WinACAD / S&P 50.24% / 11.69% |
WinACAD / S&P 40.45% / 6.81% |
LoseACAD / S&P -71.64% / 7.78% |
| 2023-Q31/3 |
LoseACAD / S&P -12.99% / -3.27% |
WinACAD / S&P 23.54% / 7.52% |
LoseACAD / S&P -31.85% / -5.03% |
| 2023-Q21/3 |
WinACAD / S&P 27.26% / 8.74% |
LoseACAD / S&P 7.51% / 9.50% |
LoseACAD / S&P -45.67% / -8.57% |
| 2023-Q11/3 |
WinACAD / S&P 18.22% / 7.50% |
LoseACAD / S&P 5.51% / 10.77% |
LoseACAD / S&P -31.58% / -15.69% |
| 2022-Q40/3 |
LoseACAD / S&P -2.69% / 7.56% |
LoseACAD / S&P 6.83% / 11.88% |
LoseACAD / S&P ACAD unavailable / -17.99% |
| 2022-Q31/3 |
WinACAD / S&P 16.11% / -4.88% |
LoseACAD / S&P 7.82% / 13.47% |
LoseACAD / S&P ACAD unavailable / -1.41% |
| 2022-Q20/3 |
LoseACAD / S&P -41.82% / -16.10% |
LoseACAD / S&P 10.58% / 13.71% |
LoseACAD / S&P ACAD unavailable / 11.04% |
| 2022-Q11/3 |
WinACAD / S&P 3.77% / -4.60% |
LoseACAD / S&P 7.60% / 15.97% |
LoseACAD / S&P ACAD unavailable / 42.23% |
| 2021-Q41/3 |
WinACAD / S&P 40.52% / 11.03% |
LoseACAD / S&P 9.60% / 15.00% |
LoseACAD / S&P ACAD unavailable / 96.40% |
| 2021-Q31/3 |
LoseACAD / S&P -31.90% / 0.58% |
WinACAD / S&P 13.20% / 10.77% |
LoseACAD / S&P ACAD unavailable / 69.42% |
| 2021-Q21/3 |
LoseACAD / S&P -5.47% / 8.55% |
WinACAD / S&P 17.88% / 6.58% |
LoseACAD / S&P ACAD unavailable / 51.81% |
| 2021-Q11/3 |
LoseACAD / S&P -51.74% / 6.17% |
WinACAD / S&P 25.14% / -1.06% |
LoseACAD / S&P ACAD unavailable / 7.39% |
| 2020-Q42/3 |
WinACAD / S&P 29.60% / 12.15% |
WinACAD / S&P 30.28% / -3.72% |
LoseACAD / S&P ACAD unavailable / -33.42% |
| 2020-Q31/3 |
LoseACAD / S&P -14.90% / 8.93% |
WinACAD / S&P 39.54% / -2.04% |
LoseACAD / S&P ACAD unavailable / -27.10% |
| 2020-Q21/3 |
LoseACAD / S&P 14.72% / 20.54% |
WinACAD / S&P 48.87% / -0.46% |
LoseACAD / S&P ACAD unavailable / -27.11% |
| 2020-Q12/3 |
WinACAD / S&P -1.24% / -19.60% |
WinACAD / S&P 53.93% / 3.47% |
LoseACAD / S&P ACAD unavailable / -14.75% |
| 2019-Q42/3 |
WinACAD / S&P 18.87% / 9.07% |
WinACAD / S&P 51.50% / 5.36% |
LoseACAD / S&P ACAD unavailable / 2.99% |
| 2019-Q32/3 |
WinACAD / S&P 34.64% / 1.70% |
WinACAD / S&P 44.53% / 5.02% |
LoseACAD / S&P ACAD unavailable / 0.21% |
| 2019-Q21/3 |
LoseACAD / S&P -0.45% / 4.30% |
WinACAD / S&P 42.67% / 6.64% |
LoseACAD / S&P ACAD unavailable / 8.65% |
| 2019-Q12/3 |
WinACAD / S&P 66.05% / 13.65% |
WinACAD / S&P 50.11% / 8.12% |
LoseACAD / S&P ACAD unavailable / 14.29% |
| 2018-Q41/3 |
LoseACAD / S&P -22.11% / -13.52% |
WinACAD / S&P 79.19% / 9.05% |
LoseACAD / S&P ACAD unavailable / 18.23% |
| 2018-Q32/3 |
WinACAD / S&P 35.95% / 7.71% |
WinACAD / S&P 122.72% / 10.21% |
LoseACAD / S&P ACAD unavailable / 19.06% |
| 2018-Q21/3 |
LoseACAD / S&P -32.04% / 3.43% |
WinACAD / S&P 193.81% / 9.03% |
LoseACAD / S&P ACAD unavailable / 14.46% |
| 2018-Q11/3 |
LoseACAD / S&P -25.37% / -0.76% |
WinACAD / S&P 385.95% / 7.68% |
LoseACAD / S&P ACAD unavailable / 12.46% |
| 2017-Q41/3 |
LoseACAD / S&P -20.07% / 6.64% |
WinACAD / S&P 620.68% / 7.03% |
LoseACAD / S&P ACAD unavailable / 13.82% |
| 2017-Q32/3 |
WinACAD / S&P 35.07% / 4.48% |
WinACAD / S&P 1632.29% / 5.68% |
LoseACAD / S&P ACAD unavailable / 17.57% |
| 2017-Q21/3 |
LoseACAD / S&P -18.88% / 3.09% |
WinACAD / S&P 40021.66% / 4.83% |
LoseACAD / S&P ACAD unavailable / 17.74% |
| 2017-Q12/3 |
WinACAD / S&P 19.21% / 6.07% |
WinACAD / S&P 53363.93% / 3.67% |
LoseACAD / S&P ACAD unavailable / 13.32% |
| 2016-Q41/3 |
LoseACAD / S&P -9.34% / 3.82% |
WinACAD / S&P 28311.48% / 2.09% |
LoseACAD / S&P ACAD unavailable / 7.05% |
| 2016-Q31/3 |
LoseACAD / S&P -2.00% / 3.85% |
WinACAD / S&P 5754.35% / 0.20% |
LoseACAD / S&P ACAD unavailable / -3.15% |
Dividend-reinvested, split-adjusted total return
1Y · 2025-08-29 to 2026-08-27
| Metric | ACAD total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 14.39% | 20.78% |
| Annualized return | 14.39% | 20.78% |
5Y · 2021-09-01 to 2026-08-27
| Metric | ACAD total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 68.06% | 83.14% |
| Annualized return | 10.94% | 12.86% |
10Y · 2016-09-01 to 2026-08-27
| Metric | ACAD total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -7.38% | 319.30% |
| Annualized return | -0.76% | 15.41% |
Calculation rules
- window
- Latest 40 completed benchmark quarters; unavailable issuer evidence remains visible and scores 0.
- return Basis
- Issuer adjusted close reinvests distributions and normalizes splits; the S&P 500 Total Return Index is the direct benchmark.
- point Rule
- Strict same-quarter win = 1. Loss, tie or unavailable evidence = 0. No partial or subjective points.
- frequency
- Quarter endpoints only.
- fundamentals
- Trailing-four-quarter issuer revenue and EPS growth use the issuer's normalized government-filed facts.
- non Scoring
Snapshot captured 2026-09-04.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |